Guggenheim Has Lowered Expectations for ArriVent BioPharma (NASDAQ:AVBP) Stock Price

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) had its target price cut by equities researchers at Guggenheim from $30.00 to $28.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s price objective would indicate a potential upside of 115.22% from the company’s current price.

Several other brokerages have also commented on AVBP. BTIG Research reiterated a “buy” rating and issued a $29.00 price target on shares of ArriVent BioPharma in a research note on Friday, October 16th. Cantor Fitzgerald restated an “overweight” rating on shares of ArriVent BioPharma in a research report on Thursday. Oppenheimer restated an “outperform” rating and issued a $25.00 target price on shares of ArriVent BioPharma in a report on Monday, October 26th. JonesTrading dropped their target price on shares of ArriVent BioPharma from $45.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. Finally, HC Wainwright cut their price target on shares of ArriVent BioPharma from $47.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, October 8th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, ArriVent BioPharma currently has an average rating of “Moderate Buy” and an average target price of $24.67.

Read Our Latest Analysis on AVBP

ArriVent BioPharma Price Performance

ArriVent BioPharma stock opened at $13.01 on Monday. ArriVent BioPharma has a 1-year low of $11.36 and a 1-year high of $35.83. The stock has a market cap of $672.92 million, a PE ratio of -3.61 and a beta of 1.66. The stock’s fifty day moving average is $21.36 and its two-hundred day moving average is $26.40.

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. The business had revenue of $5.00 million for the quarter, compared to analysts’ expectations of $0.80 million. On average, research analysts expect that ArriVent BioPharma will post -3.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AVBP. Hhlr Advisors LTD. purchased a new stake in ArriVent BioPharma during the 2nd quarter valued at approximately $136,498,000. BlackRock Inc. acquired a new position in ArriVent BioPharma in the 2nd quarter valued at $112,919,000. General Catalyst Group Management LLC acquired a new position in ArriVent BioPharma in the 2nd quarter valued at $51,929,000. Vivo Capital LLC acquired a new position in ArriVent BioPharma in the 1st quarter valued at $20,438,000. Finally, Seven Fleet Capital Management LP raised its position in ArriVent BioPharma by 390.7% during the 2nd quarter. Seven Fleet Capital Management LP now owns 246,606 shares of the company’s stock worth $8,567,000 after buying an additional 196,354 shares during the last quarter. Hedge funds and other institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

(Get Free Report)

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.

Further Reading

Analyst Recommendations for ArriVent BioPharma (NASDAQ:AVBP)

Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.